【摘要】：本文綜述了血栓病的形成機(jī)制和危害，介紹了抗血小板聚集藥物研究的意義及發(fā)展前景。 運(yùn)用新藥設(shè)計(jì)原理以及生物電子等排原理，在實(shí)驗(yàn)室前期的研究工作基礎(chǔ)上，以通過(guò)體外抗血小板聚集反應(yīng)活性初篩試驗(yàn)選出的N1, N3-二-(4-乙�；交�)-4-甲氧基-1,3-苯二磺酰胺為先導(dǎo)化合物，通過(guò)對(duì)吡考他胺兩個(gè)1,3-側(cè)鏈進(jìn)行改造，設(shè)計(jì)并合成了17種4-甲氧基-1,3-苯二磺酰胺類化合物P1~P17，其中10種未見文獻(xiàn)報(bào)道。對(duì)新近制得化合物進(jìn)行了IR和1H NMR等光譜表征分析及熔點(diǎn)測(cè)定，部分目標(biāo)化合物經(jīng)質(zhì)譜確認(rèn)。 采用Born比濁法，對(duì)17種目標(biāo)化合物進(jìn)行的體外抗血小板聚集反應(yīng)活性初篩試驗(yàn)結(jié)果表明，8種目標(biāo)化合物表現(xiàn)出不同程度的抗血小板聚集活性，高于陽(yáng)性對(duì)照藥吡考他胺(Picotamide)和阿司匹林，其中化合物P13的活性最高，IC50值為0.46。 對(duì)較高活性的化合物P10，P13，P15和P17進(jìn)行急性毒性試驗(yàn)，結(jié)果表明四種受試物都表現(xiàn)出較低的毒性，有進(jìn)一步研究開發(fā)的價(jià)值。繼續(xù)對(duì)化合物P10、P13和P15進(jìn)行與L929細(xì)胞的作用研究，實(shí)驗(yàn)結(jié)果顯示，三種受試物在中高給藥濃度下細(xì)胞存活率均相對(duì)較高，進(jìn)一步證明了目標(biāo)化合物具有較低的毒性。根據(jù)藥理試驗(yàn)結(jié)果，對(duì)目標(biāo)化合物的構(gòu)效關(guān)系做出初步的推測(cè)和總結(jié)，，為實(shí)驗(yàn)室今后類似研究工作提供了新的依據(jù)和參考。
[Abstract]:In this paper, the mechanism and harm of thrombosis were reviewed, and the significance and development prospect of antiplatelet aggregation drugs were introduced. Using the principles of new drug design and the principle of equal arrangement of biological electronics, on the basis of the preliminary research work in the laboratory, Using N _ 1, N _ 3-di-(4-acetylphenyl) -4-methoxy-3-benzenesulfonamide as a lead compound, two 1o 3- side chains of picotadamine were modified by the primary screening test of antiplatelet aggregation reaction activity in vitro. Seventeen kinds of 4-methoxy -1o 3-benzenedisulfonamide compounds P _ (1) P _ (17) have been designed and synthesized, of which 10 have not been reported in literature. The newly synthesized compounds were characterized by IR and 1H NMR spectra and the melting point was determined. Some of the target compounds were confirmed by mass spectrometry. Born turbidimetric assay was used to screen the antiplatelet aggregation activity of 17 target compounds in vitro. The results showed that 8 target compounds showed different degree of antiplatelet aggregation activity. The activity of compound P13 was higher than that of picotadine (Picotamide) and aspirin, and the highest activity of compound P13 was 0.46. The acute toxicity tests were carried out on the high activity compounds P10, P13, P15 and P17. The results showed that the four tested compounds showed lower toxicity, and were valuable for further research and development. The effects of compounds P10, P13 and P15 on L929 cells were further studied. The results showed that the cell survival rate of the three compounds was relatively high at medium and high concentrations, which further proved that the target compounds had lower toxicity. Based on the results of pharmacological tests, the structure-activity relationship of the target compounds was preliminarily speculated and summarized, which provided a new basis and reference for similar research in laboratory.
【學(xué)位授予單位】：天津理工大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R914.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 ;Synthesis and in vitro activities on anti-platelet aggregation of N,N'-di(2-substituted-phenyl)-4-methoxyisophthalamides and benzene- 1,3-disulfonamides[J];Chinese Chemical Letters;2011年10期

2 王鳳;;尿激酶治療下肢靜脈血栓50例療效觀察[J];哈爾濱醫(yī)藥;2010年02期

3 宋鵬;段蘊(yùn)鈾;楊建軍;黃友章;雷軍慧;;維拉帕米對(duì)外照射導(dǎo)致的小細(xì)胞肺癌細(xì)胞系耐藥性的逆轉(zhuǎn)作用[J];解放軍醫(yī)學(xué)雜志;2007年04期

4 徐薇;;重視血栓性疾病的診治[J];現(xiàn)代實(shí)用醫(yī)學(xué);2010年06期

5 奉濤;;溶栓藥物的臨床應(yīng)用及其進(jìn)展[J];臨床合理用藥雜志;2011年12期

6 吳邦耀;羅卓荊;孟浩;胡學(xué)昱;張永光;李沫;;膠原-明膠支架材料交聯(lián)改性的制備及細(xì)胞毒性實(shí)驗(yàn)研究[J];生物醫(yī)學(xué)工程與臨床;2007年06期

7 吳文蓓;吳文軍;;臨床用溶栓藥物的應(yīng)用和進(jìn)展[J];山西醫(yī)藥雜志;2010年01期

本文編號(hào)：2148580